Search

everythinglearnresearchcommunity

for

Search:↓

The individual is struggling with hair loss and depression, having tried treatments like Finasteride, Dutasteride, and Minoxidil, but faced side effects and limited success. They are considering a hair transplant and other options while dealing with personal challenges, including knee injuries and weight issues, and are encouraged by others to focus on self-improvement and acceptance.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

The user experienced hair shedding and follicle shrinkage when using retinoic acid, despite trying different concentrations and frequencies. The hair loss persisted for six months but regrew after stopping the treatment.

The user experienced significant hair loss after extended fasting, initially thought to be Telogen Effluvium, but later suspected male pattern baldness. They tried finasteride briefly but stopped due to concerns about side effects, and are unsure if the hair loss is due to Telogen Effluvium or another cause.

A young male in his twenties discusses hair loss, mentioning the use of Minoxidil, topical finasteride, and occasional derma rolling. He inquires about scalp inflammation, fibrosis, and the potential benefits of magnesium oil and scalp massages for improving blood flow and hair health.

Diffuse hair thinning and treatments like finasteride and minoxidil. Early detection and treatment are crucial for effective management.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

The conversation discusses potential causes of pigmentation around hair follicles, suggesting sebum buildup, autoimmune conditions, or dermatitis. Treatments mentioned include finasteride, dutasteride, and an anti-inflammatory diet, with a recommendation to consult a doctor for a proper diagnosis.

A 24-year-old male using topical finasteride for hair loss is experiencing thinning despite treatment and has high estrogen levels. He is seeking advice on whether high estrogen could be causing hair loss and how others with high estrogen levels have addressed it.

The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

The struggles of hair loss at a young age and available treatments, such as medication (Finasteride, Minoxidil, Dutasteride, Derma Rolling) and potential options for hair systems or cloning in Japan. People discussed their own experiences with trying to cope with the emotional aspects of this condition.

The user reports slow and steady hair regrowth using Finasteride (1.25mg) and topical Minoxidil (Rogaine, 2x/day), along with occasional use of Nizoral. They have stopped dermarolling.

The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

The user is experiencing significant hair shedding and suspects it may be due to low serum ferritin levels rather than worsening androgenetic alopecia. They have resumed iron supplementation and are seeking additional solutions to address the shedding.

An 18-year-old experienced initial hair improvement with minoxidil but noticed increased shedding after surgery and lifestyle changes. They suspect iron deficiency and are seeking other possible explanations for the hair loss.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

The user is using a combination of hair loss treatments including dutasteride, minoxidil, RU58841, low-level laser therapy, ketokonozole, supplements, Viviscal, Nutrafol, microneedling, PRP, and scalp Botox injections, but is still experiencing hair shedding and thinning. Despite being on this regimen for two years, the user's hair condition is worsening, and they are seeking advice on what else they can do.

The conversation discusses using cyproterone temporarily to reverse hair loss, followed by finasteride to maintain regrowth. Concerns about cyproterone's side effects, such as lowering testosterone and potential health risks, are raised, with alternatives like spironolactone suggested for androgen-related issues.

A 19-year-old is concerned about long-term microneedling for hair loss and is unsure if it will remain effective as they age. They experienced side effects from topical finasteride and are considering whether to try it again in the future, while also dealing with body dysmorphia and stress.

The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.

The conversation is about an 18-year-old's progress with hair regrowth using oral Minoxidil, dermarolling, and RU58841 over three months, starting treatment after beginning to lose hair at 16. Participants are impressed with the improvement and encourage continued treatment.